The new policy announced by the White House aims to reduce insulin costs for Medicare beneficiaries by capping the copay at $35 for certain plans starting in 2021. This is a significant step towards making insulin more affordable for seniors on Medicare. However, this policy does not apply to everyone. People who are not on Medicare, including younger individuals with diabetes, will not benefit from this price cap. The policy is expected to influence private insurance plans to follow suit, but it is not guaranteed. The new policy also requires Medicare beneficiaries to opt into specific enhanced plans to receive the savings, and it may result in higher premiums for those plans. While this is a positive development for some, there are still many people with diabetes who will continue to face high insulin costs. The policy is seen as a pilot program, and its success may lead to broader applications in the future.